Acura -6.4% AH after providing update for Aversion

|About: Acura Pharmaceuticals, Inc. (ACUR)|By:, SA News Editor

The FDA has advised Acura (ACUR) that data from its AP-ADF-301 intranasal abuse liability study for its Aversion combo drug is "insufficient to support an intranasal abuse deterrence claim."

Acura says its plans for the drug, including "a revised projected timeline" for submitting an NDA, will be determined following a meeting with the FDA.

The company adds it's "committed to developing [its] Aversion opiods products."